URSO, Luca
 Distribuzione geografica
Continente #
NA - Nord America 4.727
AS - Asia 4.030
EU - Europa 1.817
SA - Sud America 667
Continente sconosciuto - Info sul continente non disponibili 294
AF - Africa 128
OC - Oceania 10
Totale 11.673
Nazione #
US - Stati Uniti d'America 4.481
SG - Singapore 1.498
IT - Italia 854
CN - Cina 611
BR - Brasile 509
BD - Bangladesh 501
VN - Vietnam 492
HK - Hong Kong 338
DE - Germania 204
GB - Regno Unito 131
JP - Giappone 129
CA - Canada 128
FR - Francia 120
IN - India 102
FI - Finlandia 79
RU - Federazione Russa 78
NL - Olanda 74
ID - Indonesia 72
MX - Messico 70
IQ - Iraq 46
AR - Argentina 44
SE - Svezia 44
PL - Polonia 40
AT - Austria 39
ZA - Sudafrica 38
ES - Italia 34
TR - Turchia 34
CO - Colombia 28
PK - Pakistan 26
VE - Venezuela 25
LT - Lituania 21
EC - Ecuador 20
UA - Ucraina 20
MA - Marocco 18
SA - Arabia Saudita 18
TN - Tunisia 18
IR - Iran 17
BE - Belgio 16
KR - Corea 15
MY - Malesia 15
PH - Filippine 15
CL - Cile 14
PY - Paraguay 14
UZ - Uzbekistan 14
CR - Costa Rica 12
EG - Egitto 12
IL - Israele 11
AE - Emirati Arabi Uniti 10
CZ - Repubblica Ceca 10
DZ - Algeria 10
TH - Thailandia 10
KE - Kenya 9
GR - Grecia 8
JM - Giamaica 8
AZ - Azerbaigian 7
KG - Kirghizistan 7
PE - Perù 7
TT - Trinidad e Tobago 7
AU - Australia 6
TW - Taiwan 6
ET - Etiopia 5
RO - Romania 5
RS - Serbia 5
SN - Senegal 5
AO - Angola 4
CY - Cipro 4
GT - Guatemala 4
HU - Ungheria 4
JO - Giordania 4
QA - Qatar 4
BH - Bahrain 3
CH - Svizzera 3
HN - Honduras 3
HR - Croazia 3
IE - Irlanda 3
NI - Nicaragua 3
NP - Nepal 3
PT - Portogallo 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AL - Albania 2
BO - Bolivia 2
DK - Danimarca 2
GE - Georgia 2
IS - Islanda 2
MK - Macedonia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TV - Tuvalu 2
AM - Armenia 1
BB - Barbados 1
BJ - Benin 1
BN - Brunei Darussalam 1
Totale 11.355
Città #
Singapore 952
Ashburn 811
San Jose 622
Dallas 348
Hong Kong 334
Council Bluffs 302
Santa Clara 279
Beijing 226
New York 226
Los Angeles 190
Ho Chi Minh City 147
Hanoi 127
Tokyo 119
Chicago 83
Milan 83
Lauterbourg 80
Munich 68
Rome 61
Chandler 60
Buffalo 57
Bologna 55
Hefei 51
Jakarta 51
São Paulo 48
Toronto 47
Orem 45
Ferrara 44
Atlanta 41
Frankfurt am Main 39
Shanghai 39
Mexico City 38
Lappeenranta 37
London 35
Houston 34
Warsaw 34
Brooklyn 33
Montreal 30
Phoenix 30
Helsinki 29
The Dalles 26
Denver 25
Nuremberg 25
Haiphong 24
Da Nang 22
Chennai 21
Rio de Janeiro 21
Stockholm 21
Fairfield 20
Naples 20
Salt Lake City 20
Brasília 19
Johannesburg 19
Poplar 19
Amsterdam 17
Boston 17
Manchester 17
Baghdad 16
Falkenstein 16
Seattle 15
Vienna 15
Bari 14
City of London 14
Moscow 14
Mumbai 14
Wilmington 14
Istanbul 13
Tashkent 13
Turku 13
Dong Ket 12
Elk Grove Village 12
Asunción 11
Miami 11
Ottawa 11
Palermo 11
Tampa 11
Turin 11
Ankara 10
Boardman 10
Brussels 10
Dhaka 10
Figino 10
Kansas City 10
Medellín 10
Porto Alegre 10
San Francisco 10
Thái Nguyên 10
Charlotte 9
Nairobi 9
Newark 9
Parma 9
San José 9
Assago 8
Belo Horizonte 8
Buriram 8
Cagliari 8
Florence 8
Hải Dương 8
Las Vegas 8
Manaus 8
Caracas 7
Totale 6.765
Nome #
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? 252
90 Y/177 Lu‐dotatoc From Preclinical Studies to Application in Humans 238
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 225
Atypical Metastases from Prostate Cancer: Alpha-Methylacyl-Coenzyme A Racemase (AMACR) as a Potential Molecular Target in Prostate-Specific Membrane Antigen-Negative Prostate Adenocarcinoma 212
18F-FDG PET/CT radiomic analysis and artificial intelligence to predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients 202
The Role of [68Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review 197
Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial 178
ML Models Built Using Clinical Parameters and Radiomic Features Extracted from 18F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer 178
99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications 177
The Role of [18F]F-Choline PET/CT in the Initial Management and Outcome Prediction of Prostate Cancer: A Real-World Experience from a Multidisciplinary Approach 177
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review—Part 1 oncological setting 176
Is There a Role for FAPI PET in Urological Cancers? 174
Complicated Inguinal Hernia Incidentally Detected on a Radiolabelled Autologous White Blood Cell Scan 174
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review– part 2 173
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study) 171
MONTE CARLO SIMULATIONS IN RADIO-LIGAND THERAPY WITH LU-177 FOR NEUROENDOCRINE TUMOURS (NETS) 170
Relevance of Volumetric Parameters Applied to [68Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT 168
Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE 165
Rhenium Radioisotopes for Medicine, a Focus on Production and Applications 163
PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review 163
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer 161
Clinical-diagnostic relevance of breast “incidentaloma” detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: Correlation with radiological imaging and histopathology 161
Positron Emission Tomography-Derived Radiomics and Artificial Intelligence in Multiple Myeloma: State-of-the-Art 159
Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET) 159
PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature 158
[18F]FDG PET-TC radiomics and machine learning in the evaluation of prostate incidental uptake 157
68Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives 154
Role of 18F-FDG PET/CT in evaluating lymph node status in patients with head and neck squamous cell carcinoma 152
Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study 150
Radioligand therapy in sympathetic-adrenal-medullary axis tumors: state of art and perspectives 150
18F-FDG PET-Derived Volume-Based Parameters to Predict Disease-Free Survival in Patients with Grade III Breast Cancer of Different Molecular Subtypes Candidates to Neoadjuvant Chemotherapy 150
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives 149
[18F]-FDHT PET for the Imaging of Androgen Receptor in Prostate and Breast Cancer: A Systematic Review 147
68Ga-PSMA-11 PET/CT in Bilateral Clear Cell Renal Cell Carcinoma: an Intra-patient Comparison Between High and Low Grade Tumors 145
Impact of Metastasis-directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT Study 144
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score 143
Comparison of MRI vs. [18F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives 143
Uncommon solitary nasal extramedullary plasmacytoma detected by 18F-FDG PET/CT 142
Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer 138
FDG PET/CT Volume-Based Quantitative Data and Survival Analysis in Breast Cancer Patients: A Systematic Review of the Literature 136
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer 136
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer 135
Diagnostic Accuracy of PET with 18F-Fluciclovine ([18F]FACBC) in Detecting High-Grade Gliomas: A Systematic Review and Meta-Analysis 128
Artificial intelligence & nuclear medicine: an emerging partnership 127
COMPARISON BETWEEN CLINICAL DOSIMETRIC PLATFORMS IN NET PATIENTS TREATED WITH PRRT 127
The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness 125
18F-FDG PET/CT Radiomics for Predicting Therapy Response in Primary Mediastinal B-Cell Lymphoma: A Bi-Centric Pilot Study 124
Considerations on the preliminary results of the NETTER-2 trial: is the glass half full or half empty? 123
Incidental findings of acute myeloid leukemia in Sjögren's syndrome detected by nuclear medicine techniques 122
Cavernous Hepatic Hemangioma at 18F‑Choline Positron Emission Tomography–Computed Tomography: Be Aware of the Pitfall 121
Insights into pet-based radiogenomics in oncology: an updated systematic review 120
Right Atrium Mass Assessed with 18F-FDG PET/CT Scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report 120
Superscan-Like Pattern on 18F-Choline PET/CT in a Patient With Essential Thrombocythemia 119
ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors 118
Misinterpretation of an inflammatory FDG uptake in a patient treated for Hodgkin lymphoma: a case report 118
Safire CT iterative reconstruction protocol to reduce patient effective dose on PET/CT examinations 117
18 F-Choline Versus 68 Ga-PSMA-11 PET/CT Imaging Comparison in Incidental Clear Cell Renal Cell Carcinoma 114
[99mTc]Tc-sestamibi for the differential diagnosis of renal masses: a study protocol 109
Radiomics Results for Adrenal Mass Characterization Are Stable and Reproducible Under Different Software 107
Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review 105
The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective 103
Lymphoid organs’ metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy: an exploratory study 98
Extramedullary disease in multiple myeloma: what you might not expect on [18F]FDG PET/CT - a pictorial essay 95
Triple Tracer PET in Advanced Prostate Cancer: Chasing Phenotypic Plasticity 92
One scan, many stories: deep learning for signal separation in multi-tracer PET imaging 91
PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview 87
Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000-2022) 84
The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential 84
The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria 84
The Future Direction of Women in Nuclear Medicine and Nuclear Medicine in Women's Health 84
Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study 83
PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality? 83
18 F-FDG PET/CT Volumetric Metabolic Parameters in the Staging of Head and Neck Squamous Cell Carcinoma 79
Molecular imaging of PARP in cancer: state-of-the-art 79
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON? 77
Synthetic imaging for research and education in nuclear medicine: Who’s afraid of the black box? 76
Radionuclide-based nanotechnologies in triple-negative breast cancer: current evidence and future perspectives 75
Phosphorus-32 microparticles for locally advanced pancreatic cancer: how and when? 75
Clinical applications of long axial field-of-view PET/CT scanners in oncology 75
Radioligand Therapy with Radiolabeled Somatostatin Analogues in Metastatic Bronchial Carcinoid: an Impressive Response 73
The Role of Molecular Imaging in Patients with Brain Metastases: A Literature Review 70
The expanding role of next-generation imaging in prostate cancer management: a cross-sectional survey exploring the clinical practice of uro-oncologists in North-Eastern Italy; on behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est) 67
Hepato-Biliary Imaging in an Acute Setting: Is There a Role for Nuclear Medicine? 66
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting 66
AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy 64
Initial results of the use of a novel semiquantitative parameter in three-phase bone scan to predict 99mTc-HMPAO-labeled leukocyte scintigraphy in patients with unilateral total knee replacement 64
Molecular Imaging Advances in Endometriosis: The Promise of Radiopharmaceuticals 62
Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights 58
Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach 57
Molecular Imaging in Cancer Chemoresistance: What’s Brewing? 50
The Value of FDG PET/CT in Penile Cancer: An Update 40
Real-world, multicenter assessment of 18 F-FDG PET/CT prognostic value in triple-negative breast cancer (TRINE-PET): the study protocol 30
Diagnostic accuracy of 18F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study 28
The future of nuclear medicine in Italy 27
Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms 23
Illuminating Multiple Sclerosis: Next-Generation PET Tracers for Molecular Insights 21
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings 17
The value of [18F]FDG PET/CT in fever of unknown origin (FUO): an update and future aspects 14
Editorial: Recent developments in artificial intelligence and radiomics 7
Colorectal Cancer: A Landscape of New Potential Radiopharmaceuticals 7
Totale 11.661
Categoria #
all - tutte 49.774
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.774


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202259 0 0 0 2 5 4 7 2 5 3 15 16
2022/2023186 7 15 3 17 21 20 18 18 14 2 42 9
2023/2024371 11 24 29 14 40 45 12 47 18 12 40 79
2024/20252.312 74 87 190 104 235 144 87 110 369 304 357 251
2025/20268.085 609 308 687 908 979 421 936 440 725 841 779 452
2026/2027595 358 237 0 0 0 0 0 0 0 0 0 0
Totale 11.673